Observational Study on AHSCT and HE-DMT for Multiple Sclerosis
An observational study planned to enroll about 2000 participants with relapsing-remitting or primary progressive multiple sclerosis to assess responses to autologous haematopoietic stem cell transplantation (AHSCT) and high-efficacy disease-modifying therapies (HE-DMT). No results or endpoints have been posted yet.
- Tags
- #MSResearch
- Most relevant to
- —
- Source
- Read original source
- Human efficacy
- Not established from this source
- Mechanism
- Not reported
- Evidence strength
- No results yet
- Outcome
- Not reported
Why it matters
This research aims to explore the effectiveness of AHSCT and HE-DMT in achieving No Evidence of Disease Activity (NEDA-3), which is a significant goal in MS treatment.
What this does not prove
No results are posted, and planned enrollment and endpoints are not findings. This means that conclusions cannot yet be drawn from the data.
Next milestone
No next milestone was established from the available source.
Study facts
- Study design
- Observational
- Participants / samples
- 2000 · planned enrolment
- Randomised
- Not reported
- Controlled
- Not reported
- Primary endpoint met
- Not reported
- Relevant MS type
- RRMS, PPMS
- Publication date
- Not reported
- Evidence reviewed
- Trial registry record
- Regulatory approval
- Not reported
- Research areas
- Not classified
- Biological target
- Not reported
- Pathway
- Not reported
- Population
- Not reported
- Size of effect
- Not reported
- Secondary endpoints
- Not reported
- MRI endpoints
- Not reported
- Biomarkers
- Not reported
- Safety
- Not reported
Original sources
- Trial registrationREAL-MS: Observational Database Study of AHSCT and MS Therapies ↗
Supporting passages (12)
study phaseStudy type: Observational
study designStudy type: Observational
subjectsParticipants: people; ages from 18 Years; sex All
sample sizeEnrollment: 2000 participants (estimated)
findingsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
limitationsTrial registry record. Publication date: unknown. No results are posted. Planned enrolment and endpoints are not findings.
peer reviewedTrial registry record.
primary endpointPrimary endpoints: No Evidence of Disease Activity (NEDA-3)
relevant ms typesConditions: Multiple Sclerosis; Multiple Sclerosis (MS) - Relapsing-remitting; Multiple Sclerosis (MS) Primary Progressive
interventionInterventions: Autologous haematopoietic stem cell transplantation (AHSCT); High-efficacy disease-modifying therapy (HE-DMT)
follow upFollow-up: From treatment baseline through study completion, up to 24 years
sample size basisEnrollment: 2000 participants (estimated)
AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.